Aquestive Therapeutics is trading 7.22% up now at $4.60 after positive Anaphylm human-factors and pharmacokinetic results supported its planned third-quarter 2026 FDA resubmission.
- Revised packaging cut median pouch-opening time from 17 seconds to 3; self-administered pharmacokinetics matched clinician administration.
- The study showed fewer administration errors, no torn films, and clinically meaningful pharmacodynamic response after purposeful top-of-tongue placement, directly addressing issues in FDA’s January 2026 Complete Response Letter.
- Second-quarter results are scheduled after market close on August 11, 2026.